PCSK9 and metabolic syndrome: The European Society of Cardiology/European Atherosclerosis Society guidelines recommend considering the early addition of a PCSK9 inhibitor for the management of dyslipidemia in patients who present with ACS and have elevated LDL-C levels despite treatment with ezetimibe and a maximally tolerated dose of statins [17].